Although the prior authorization process for direct-acting antiviral agents to treat hepatitis C has become significantly less arduous and time-consuming than it was when these drugs were first introduced, managing the third-party payor aspect of DAA therapy can still be a significant burden for many clinical practices.
A new study from the Icahn School of Medicine at Mount Sinai, in New York City, suggests that specially trained patient navigators, working in collaboration with nursing and